Coronavirus and Atopic Dermatitis (AD) / Alopecia Reporting Database
Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with atopic dermatitis (AD) or alopecia who are treated with or without systemic immunomodulating medication, we have created a number of secure, online, de-identified Personal Health Identifier (PHI) – free reporting registries and an anonymous patient reported survey.
We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia and atopic dermatitis patients treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). Please follow the links below to register by clicking on either of the physician entered registry logos.
If you are a patient with atopic dermatitis and have developed COVID-19 we encourage you to complete the anonymous survey by clicking on the green SECURE-AD Patients survey logo.
Thank you in advance for your participation.
SECURE-AD update: current data
We are incredibly grateful for your ongoing contributions to the international atopic dermatitis and COVID-19 reporting registries. We recently analysed the early results of patients with atopic dermatitis who developed COVID-19. There are currently 223 cases reported in the SECURE-AD Registry. To 529 patients registered themselves in the SECURE-AD Patient Survey, of whom 187 contracted COVID-19. You can find the first results below.
Please use the following citation if referencing the data on this page: Alan Irvine, Carsten Flohr, Phyllis Spuls, Angela Bosma, Conor Broderick, Ching-Chi Chi, Aaron Drucker, Kenji Kabashima, Annelie Musters, David Prieto-Merino, Dmitri Wall, Bernd Arents, Tim Burton. SECURE-AD Database Public Data Update. www.secure-derm.com. Accessed on MM/DD/YY.